Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 2007Updated Jul 31, 2026

AbaloparatideClinical Trials.

A source-linked view of every Abaloparatide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
25
Recruiting
2
Completed
14
Terminated
1
Results posted
11
Average enrollment
249
Countries
16
Highest phase
Phase 4

Largest indexed study

22,054 participants · NCT04974723 →

Developer / research origin

Radius Health

Evidence summary

Activity is not efficacy.

Abaloparatide appears in 25 indexed studies: 2 recruiting, 14 completed and 11 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Abaloparatide is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

2007—2026

200720112012201220182018201920192020202120212022202320242024202520252026

Velocity

Abaloparatide studies by start year

Study start year · indexed snapshot

4321020072007: 1 trials2008: 0 trials2009: 0 trials2010: 0 trials20112011: 1 trials2012: 2 trials2013: 0 trials2014: 0 trials20152015: 0 trials2016: 0 trials2017: 0 trials2018: 2 trials20192019: 4 trials2020: 4 trials2021: 3 trials2022: 1 trials20232023: 1 trials2024: 2 trials2025: 3 trials20262026: 1 trials

Development

Trials by phase

Early Phase 10
Phase 15
Phase 27
Phase 37
Phase 43

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 7 studies
Showing 6 of 14 studies

Full study index

Search Abaloparatide trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

25 matching studies

Latest publications

Follow the paper trail.

PMID 26144908 ↗Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2.Linked from NCT04467983PMID 19584192 ↗Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009 Oct;94(10):3772-80. doi: 10.1210/jc.2008-2719. Epub 2009 Jul 7.Linked from NCT04467983PMID 23281041 ↗Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013 Jun;28(6):1328-36. doi: 10.1002/jbmr.1853.Linked from NCT04467983PMID 25393645 ↗Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.Linked from NCT04467983PMID 24517156 ↗Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11.Linked from NCT04467983PMID 26333733 ↗Maradit Kremers H, Larson DR, Crowson CS, Kremers WK, Washington RE, Steiner CA, Jiranek WA, Berry DJ. Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97. doi: 10.2106/JBJS.N.01141.Linked from NCT04167163PMID 17403800 ↗Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5. doi: 10.2106/JBJS.F.00222.Linked from NCT04167163PMID 25368498 ↗Chang CB, Kim TK, Kang YG, Seong SC, Kang SB. Prevalence of osteoporosis in female patients with advanced knee osteoarthritis undergoing total knee arthroplasty. J Korean Med Sci. 2014 Oct;29(10):1425-31. doi: 10.3346/jkms.2014.29.10.1425. Epub 2014 Oct 8.Linked from NCT04167163

Related pages

Keep researching Abaloparatide.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

DatabaseAbaloparatide database page →Research guideRead the Abaloparatide guide →Lab reportsSearch the COA ledger →Source registrySearch ClinicalTrials.gov ↗